The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

Autor: Albert Grinshpun, Sara M. Tolaney, Harold J. Burstein, Rinath Jeselsohn, Erica L. Mayer
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: npj Breast Cancer, Vol 9, Iss 1, Pp 1-4 (2023)
Druh dokumentu: article
ISSN: 2374-4677
50643924
DOI: 10.1038/s41523-023-00520-7
Popis: The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the first-line setting for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Randomized trials have demonstrated similar and significant improvements in progression-free survival using the three available CDK4/6 inhibitors and led to regulatory approval. However, mature overall survival data now suggest potential differences among the various agents, suggesting an evolution in selection preferences.
Databáze: Directory of Open Access Journals
Externí odkaz: